AU2003237493A1 - Methods for treating diseases or conditions with peptide constructs - Google Patents

Methods for treating diseases or conditions with peptide constructs

Info

Publication number
AU2003237493A1
AU2003237493A1 AU2003237493A AU2003237493A AU2003237493A1 AU 2003237493 A1 AU2003237493 A1 AU 2003237493A1 AU 2003237493 A AU2003237493 A AU 2003237493A AU 2003237493 A AU2003237493 A AU 2003237493A AU 2003237493 A1 AU2003237493 A1 AU 2003237493A1
Authority
AU
Australia
Prior art keywords
conditions
methods
treating diseases
peptide constructs
constructs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003237493A
Other languages
English (en)
Inventor
Yupin Charoenvit
Kenneth S. Rosenthal
Mike Whelan
Daniel H. Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cel Sci Corp
Original Assignee
Cel Sci Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cel Sci Corp filed Critical Cel Sci Corp
Publication of AU2003237493A1 publication Critical patent/AU2003237493A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003237493A 2002-01-23 2003-01-23 Methods for treating diseases or conditions with peptide constructs Abandoned AU2003237493A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US34998202P 2002-01-23 2002-01-23
US34998302P 2002-01-23 2002-01-23
US35003202P 2002-01-23 2002-01-23
US60/349,982 2002-01-23
US60/350,032 2002-01-23
US60/349,983 2002-01-23
PCT/US2003/001816 WO2003061589A2 (en) 2002-01-23 2003-01-23 Methods for treating diseases or conditions with peptide constructs

Publications (1)

Publication Number Publication Date
AU2003237493A1 true AU2003237493A1 (en) 2003-09-02

Family

ID=27617581

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003237493A Abandoned AU2003237493A1 (en) 2002-01-23 2003-01-23 Methods for treating diseases or conditions with peptide constructs

Country Status (5)

Country Link
US (1) US20070003542A1 (https=)
EP (1) EP1485466A4 (https=)
JP (1) JP2005523891A (https=)
AU (1) AU2003237493A1 (https=)
WO (1) WO2003061589A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529065A (ja) * 2002-01-23 2005-09-29 セル−サイ・コーポレーシヨン 疾患を治療するためのペプチド構築物
US8034773B2 (en) * 2004-02-05 2011-10-11 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
US8178649B2 (en) * 2004-12-07 2012-05-15 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
US7811995B2 (en) * 2006-12-13 2010-10-12 Susavion Biosciences, Inc. Therapeutic and diagnostic peptides
US8496942B2 (en) * 2006-12-13 2013-07-30 Susavion Biosciences, Inc. Therapeutic peptides and uses thereof
WO2010085661A1 (en) * 2009-01-23 2010-07-29 Musc Foundation For Reasearch Development Modified peptides and their use
WO2014165164A2 (en) * 2013-03-12 2014-10-09 Albany Medical College Compositions and methods for treating autoimmune diseases
JP6740250B2 (ja) 2015-04-27 2020-08-12 スサヴィオン バイオサイエンシーズ インコーポレイテッド がんおよび持続性ウイルス感染を処置するための組成物および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106840A (en) * 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
US5776746A (en) * 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
EP1030819A4 (en) * 1997-09-30 2001-11-21 Cel Sci Corp CONJUGATED IMMUNOGENIC POLYPEPTIDE FOR THE TREATMENT OF HERPES SIMPLEX VIRUS
WO2001036448A2 (en) * 1999-10-27 2001-05-25 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
AU4705201A (en) * 1999-10-27 2001-06-25 Cel-Sci Corporation Peptide constructs for treating autoimmune and related diseases
US6951647B2 (en) * 2001-05-24 2005-10-04 Cel-Sci Corporation T cell binding ligand peptides and method of inducing a cellular immune response
JP2005529065A (ja) * 2002-01-23 2005-09-29 セル−サイ・コーポレーシヨン 疾患を治療するためのペプチド構築物

Also Published As

Publication number Publication date
US20070003542A1 (en) 2007-01-04
EP1485466A4 (en) 2005-09-14
WO2003061589A3 (en) 2004-05-27
JP2005523891A (ja) 2005-08-11
WO2003061589A2 (en) 2003-07-31
EP1485466A2 (en) 2004-12-15

Similar Documents

Publication Publication Date Title
AU2003228449A1 (en) Directed protein docking algorithm
AU2003233312A1 (en) Pet treat
AU2003275126A1 (en) Hemiasterlin derivatives for treating resistant tumors
AU2003287642A1 (en) Process for solubilizing protein
AU2003280298A1 (en) Methods for the biological treatment of gas
AUPS160602A0 (en) Therapeutic method
AU2003272454A1 (en) Protein purification
AU2003237493A1 (en) Methods for treating diseases or conditions with peptide constructs
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003210594A1 (en) Peptide constructs for treating disease
AU2003202694A1 (en) Torero protein
AU2003236374A1 (en) Atopic dermatitis-inducing proteins
AU2003254001A1 (en) Novel htnfsf13b protein variants
AU2003278718A1 (en) Stars-a muscle-specification-binding protein
AU2003232176A1 (en) Protein c variants with altered properties
AU2003270055A1 (en) Neurotransmission-associated proteins
AU2002100577A4 (en) Horticultural treatment process
AU2003248679A1 (en) Treating disease using radium-225
AU2002368547A1 (en) Methods of sterilizing with dipercarboxylic acids
AU2003231937A1 (en) Therapeutic methods
AU2003300785A1 (en) Carbohydrate-associated proteins
AU2003229752A1 (en) Human rhomboid-related protein
AU2003254865A1 (en) Akt2-BINDING PROTEIN
AU2003300471A1 (en) Methods for treating ocular diseases
HK1076863A (en) Targeted therapeutic proteins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase